bioMérieux leverages artificial intelligence for diagnostics with new partnership
This partnership aims to develop innovative solutions to improve the accuracy and efficiency of in vitro diagnostic tools and the detection of antibiotic resistance.
FRANCE – bioMérieux, a French in-vitro diagnostics company, has partnered with Mila – Quebec Artificial Intelligence Institute to harness artificial intelligence for diagnostics.
This partnership aims to develop innovative solutions to improve the accuracy and efficiency of in vitro diagnostic tools and the detection of antibiotic resistance.
Through a collaborative research project, the two organisations aim to develop an AI model applied to genomic analysis, projected to improve antibiotic resistance prediction, and thus the value of genomic information for diagnosing infectious diseases.
Additionally, bioMérieux will benefit from access to Mila’s scientific and technological resources, enabling bioMérieux’s research teams to keep up with the latest advances in AI and offering recruitment opportunities for young researchers.
“We are joining forces with a partner with an international reputation in applied research and a vast pool of talent. For us, it’s a vector for development, enabling us to go even further in diagnostic innovation”, bioMérieux´s Executive Vice-President, Research and Development, Céline Roger-Dalbert, commented.
Mila – Quebec Artificial Intelligence Institute, founded by Yoshua Bengio, and based in Montreal, is recognised for its expertise and significant contributions in deep learning – areas of modeling language, machine translation, object recognition and generative models.
With a community of over 1,300 researchers, Mila’s mission is to be a global pole for scientific advances that inspires innovation and the progress of AI for the benefit of all, focusing on core research areas such as health, environment and climate change, and AI ethics.
They conduct research using an Open Science approach to promote collaboration and foster knowledge transfer.
“The fight against antimicrobial resistance is a major public health challenge, and AI represents a unique opportunity to accelerate the development of diagnostic tools. Mila is pleased to welcome bioMérieux, a world leader in in vitro diagnostics, to its community of partners,” said Stéphane Létourneau, Executive Vice-President of Mila.
By pioneering diagnostic solutions, bioMérieux helps clinicians improve patient care and allows industries to prevent contamination of the food and pharmaceuticals they produce.
The company invests 12% of its annual sales in R&D to design cutting-edge diagnostic solutions. This partnership with Mila further illustrates the quest for innovation at the heart of bioMérieux’s public health mission.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
